Clinical Trial Detail

NCT ID NCT02012231
Title Phase I/IIa Study to Evaluate the Safety, PK, PD, and Preliminary Efficacy of PLX8394 in Patients With Advanced Cancers.
Recruitment Terminated
Gender both
Phase Phase Ib/II
Variant Requirements Yes
Sponsors Plexxikon
Indications

thyroid gland cancer

melanoma

Advanced Solid Tumor

hairy cell leukemia

Therapies

PLX8394

Age Groups: senior adult

Additional content available in CKB BOOST